Product Description
TOT Biopharma are developing TAB-008, an intravenous drug candidate for the treatment of EGFR Wild-type Non-squamous Non-small Cell Lung Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05427305?term=TAB-008&draw=2&rank=1)
Mechanisms of Action: VEGF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Capital Medical University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20170244 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2020-03-24 |
|
| TOT-CR-TAB008-Ⅲ-01 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2020-03-24 |
|
| ChiCTR-IIR-16009827 | N/A |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2017-11-30 |